Ultra-LEAF™ Purified anti-human IL-18BP Antibody, IL-18BP, W19089C,BioLegend,947703

Host

Rat

Reactivity

Human

Application

Neut - Quality tested

Platform ID

BAB708239406

BioLegend

Headquarters

8999 BioLegend Way San Diego, CA 92121 United States

Contact

Tel: 1-858-455-9588
Fax: +49 (4131) 7023913

Email:

Product Specifications
Scientific Background

Specifications

NameUltra-LEAF™ Purified anti-human IL-18BP Antibody, IL-18BP, W19089C
Cat. No.947703
HostRat
RRIDAB_2910511 (BioLegend Cat. No. 947703)AB_2910511 (BioLegend Cat. No. 947704)
IsotypeRat IgG2a, λ
ReactivityHuman
ApplicationNeut - Quality tested
ClonalityMonoclonal
Clone NumberW19089C
ConcentrationThe antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in ourCertificate of Analysisonline tool.
TargetIL-18BP
ImmunogenRecombinant human IL-18BP
PurityThe Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Formulation0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
StorageThe antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Regulatory StatusResearch Use Only

Scientific Background

IL-18 binding protein (IL-18BP) binds to IL-18 with high affinity (Kd = 400 pM), neutralizes IL-18 activity and binds to IL-18 in a stoichiometric ratio. IL-18 belongs to the Interleukin-1 family and is a potent inflammatory cytokine. IL-18 is secreted by macrophages and dendritic cells and is expressed constitutively even in the absence of an inflammatory stimulus. IL-18 induces IFN-γ production, in the presence of IL-12 or IL-15, from Th1 cells. In addition, IL-18 promotes FasL-mediated cytotoxicity by NK cells. IL-18 has been associated with inflammatory and autoimmune diseases such as emphysema, metabolic syndromes, inflammatory bowel disease, and sepsis among others. IL-37 also interacts with IL-18BP at limiting concentrations of IL-18BP and at a 50- to 100-fold molar excess of IL-37. This interaction increases the inhibitory effect of IL-18BP on IL-18-induced IFN-γ in an NK cell line. IL-18 and IL-18BP are elevated in patients with eczema; also, IL-18 and IL-18BP are high in serum of patients with chronic liver disease. In addition, patients with heart failure have shown increases in IL-18 but decreases in IL-18BP levels. Currently, IL-18BP is in a clinical trial for the treatment of Adult-Onset Still’s disease, an inflammatory disease, which is characterized by high levels of IL-18 in plasma.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.